LexDanaLexDanabeta
Inventor

Arthur G. Taveras

Inventor
Rockaway, NJ, US

Overview

72→
Patents
1997–2019
Patent span
Chemistry
Primary field (CPC C)

Patents· 72 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds36%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes16%
C07CAcyclic or carbocyclic compounds10%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium7%
C07BGeneral methods of organic chemistry2%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,166,250Bicyclic aryl sphingosine 1-phosphate analogs201910,081,646Heterobicyclic sphingosine 1-phosphate analogs201810,017,506ATX modulating agents20189,944,666Compounds that are S1P modulating agents and/or ATX modulating agents20189,850,206S1P and/or ATX modulating agents20179,827,258Bicyclic aryl sphingosine 1-phosphate analogs20179,771,326'S1P and/or ATX modulating agents'20179,708,353'Heterobicyclic sphingosine 1-phosphate analogs'20179,572,824'Bicyclic aryl sphingosine 1-phosphate analogs'20179,555,050'ATX modulating agents'20179,550,798'Compounds that are S1P modulating agents and/or ATX modulating agents'20179,522,889'ATX modulating agents'20169,186,367'Bicyclic aryl sphingosine 1-phosphate analogs'20159,181,191'Heterobicyclic sphingosine 1-phosphate analogs'20158,835,441'Heterobicyclic metalloprotease inhibitors'20148,802,659'Bicyclic aryl sphingosine 1-phosphate analogs'20148,546,359'Bicyclic aryl sphingosine 1-phosphate analogs'20138,349,849'Heterobicyclic sphingosine 1-phosphate analogs'20138,269,043'Bicyclic aryl sphingosine 1-phosphate analogs'20128,207,221'Crystalline polymorphs of a CXC-chemokine receptor ligand'20128,076,330'Dipeptidyl peptidase-IV inhibitors'20117,964,646'3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands'20117,960,433'Treatment of chemokine mediated diseases'20117,947,720'3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands'20117,795,245'Heterobicyclic metalloprotease inhibitors'20107,786,149'Thiadiazoles as CXC- and CC- chemokine receptor ligands'20107,749,996'Heterotricyclic metalloprotease inhibitors'20107,713,966'Heterobicyclic metalloprotease inhibitors'20107,691,851'Metalloprotease inhibitors containing a heterocyclic moiety'20107,691,856'Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands'20107,671,212'Isothiazole dioxides as CXC- and CC-chemokine receptor ligands'20107,553,861'Dipeptidyl peptidase-IV inhibitors'20097,338,968'Thiadiazoles AS CXC- and CC- chemokine receptor ligands'20087,326,729'CXCR1 and CXCR2 chemokine antagonists'20087,132,445'3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands'20066,903,131'3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists'20056,878,709'3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists'20056,800,636'Farnesyl protein transferase inhibitors'20046,740,661'Farnesyl protein transferase inhibitors'20046,576,639'Compounds for the inhibition of farnesyl protein transferase'20036,492,381'Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'20026,432,959'Inhibitors of farnesyl-protein transferase'20026,426,352'Sulfonamide inhibitors of farnesyl-protein transferase'20026,387,905'Compounds useful for inhibition of farnesyl protein transferase'20026,372,747'Farnesyl protein transferase inhibitors'20026,365,588'Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'20026,362,188'Farnesyl protein transferase inhibitors'20026,300,338'Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases'20016,242,458'Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'20016,228,856'Compounds useful for inhibition of farnesyl protein transferase'20016,214,828'Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease'20016,143,758'Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases'20006,124,295'Compounds useful for inhibition of farnesyl protein transferase'20006,075,025'Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'20006,071,907'Tricyclic compounds useful as FPT inhibitors'20006,051,582'Compounds useful for inhibition of farnesyl protein transferase'20006,040,305'Compounds useful for inhibition of farnesyl protein transferase'20006,030,982'Compounds useful for inhibition of farnesyl protein transferase'20005,985,879'Compounds useful for inhibition of farnesyl protein transferase'19995,977,128'Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'19995,965,570'Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase'19995,958,940'Tricyclic compounds useful as inhibitors of farnesyl-protein transferase'19995,958,890'Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'19995,945,429'Compounds useful for inhibition of farnesyl protein transferase'19995,877,177'Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'19995,874,442'Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease'19995,861,395'Compounds useful for inhibition of farnesyl proteins transferase'19995,807,853'Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases'19985,728,703'Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'19985,721,236'Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'19985,719,148'Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases'19985,696,121'Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2012Patents assigned to SCHERING CORP (44)· patent assignee history
1997–2003Based in Rockaway, NJ, US· patent location history
2000–2011Based in Denville, NJ, US· patent location history
2005–2011Patents assigned to PHARMACOPEIA DRUG DISCOVERY (6)· patent assignee history
2008–2014Based in Southborough, MA, US· patent location history
2011–2014Patents assigned to TAVERAS ARTHUR G (7)· patent assignee history
2012–2015Patents assigned to BIOGEN IDEC INC (5)· patent assignee history
2015–2019Patents assigned to BIOGEN MA INC (14)· patent assignee history
2015–2019Based in Boston, MA, US· patent location history
2017Based in Cambridge, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SCHERING CORP441997–2012
BIOGEN MA INC142015–2019
TAVERAS ARTHUR Gself72011–2014
PHARMACOPEIA DRUG DISCOVERY62005–2011
BIOGEN IDEC INC52012–2015
Locations
LocationPatentsSpan
Rockaway, New Jersey, US291997–2003
Southborough, Massachusetts, US192008–2014
Boston, Massachusetts, US122015–2019
Denville, New Jersey, US102000–2011
Cambridge, Massachusetts, US22017